Open AccessThe Phase 3 Study ECHELON‐1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered
Author(s) -
Borchmann Peter,
Fosså Alexander,
DługoszDanecka Monika,
Böll Boris,
Dietlein Markus,
Kobe Carsten,
Goergen Helen,
Engert Andreas
Publication year - 2018
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000052
Subject(s) - brentuximab vedotin , medicine , oncology , tolerability , abvd , antibody drug conjugate , classical hodgkin lymphoma , dacarbazine , malignancy , lymphoma , chemotherapy , hodgkin lymphoma , vincristine , adverse effect , cyclophosphamide , antibody , immunology , monoclonal antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom